Keywords: Adolescents, Drug Development
Motivation: Medication response in adolescent depression is unpredictable and relationships between dose, brain concentrations and clinical response are unknown.
Goal(s): 19F-MRS is uniquely suited to study pediatric brain disposition, as it’s non-invasive, non-radiolabeled and less than minimal risk.
Approach: Youth (n=52) aged 12-21 taking fluoxetine completed 19F-MRS at 3T.
Results: Brain fluoxetine concentrations exceeded plasma concentrations by 9 to 304-fold. Dose-normalized brain concentrations varied 13-fold, explained by plasma concentration and dose with small contributions from BMI, CYP2D6 and ABCB1. 19F-MRS is a valuable tool for studying pediatric brain disposition of fluorine-containing medications and enables inquiry into patient factors that impact brain exposure and response.
Impact: In vivo 19F-MRS measures brain concentrations of fluorine-containing medications and enables inquiry into individual-level factors contributing to brain disposition. This approach fills a critical gap in pediatric drug development, especially where other imaging modalities (e.g., PET) are not feasible.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords